Lumen Bioscience develops oral antibody therapeutics.

U.S. Department of Defense

U.S. Army Medical Research & Development Command

Medical Technology Enterprise Consortium

CARB-X

US Department of Energy

Avista Development

Bioeconomy Capital

WestRiver Group

Columbia Pacific Advisors

Lumen Bioscience

Brian Finrow discusses how the forever war against human #microbial pathogens desperately needs #innovation, but fresh thinking is needed to restore the R&D pipeline. #drugdevelopment

https://lnkd.in/ezHuy92R

We are pleased to announce $5.5 million in new funding from the U.S. Department of Defense, operating through the Medical CBRN Defense Consortium (MCDC), to develop enabling technologies for needle-free vaccines. This new technology could expand access and ease vaccine production, storage, and administration in future public health emergencies.

Read the announcement below,

https://lnkd.in/gEPvt65J

#needlefree #vaccine #seattle #wa #fundingnews #mcdc #biotech #publichealth #vaccinedevelopment

"The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy."

Check out Brian Finrow's (Lumen, CEO) new opinion piece in STAT on why scalable, preventive biologic drugs sidestep the market failure issues that block bedevil conventional antibiotics development.

Read below, 

#statnews #lumenbio #seattle #wa #biotech #biologics #biologicdrugs #antibiotics #article

https://lnkd.in/gMF3qVQ9

We are pleased to announce a $16.2 million award by the U.S. Department of Defense to advance LMN-201 through late-stage trials. LMN-201 is an investigational, orally delivered biologic drug to treat and prevent C. difficile infection (CDI).

Read the full release below, 

#cdiff #lumenbio #seattle #wa #clinicaltrial #biotech

https://lnkd.in/gyE_E6tN

Cue Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing a novel class of biologic drugs for a broad range of cancers and autoimmune disorders.

Cue Biopharma Inc

Kindred Biosciences is a biopharmaceutical company that focuses on developing innovative biologic drugs for the treatment of companion animals.

Kindred Biosciences

Lumen is a biotechnology company focused on synthetic biology, protein design, and immunology to create a portfolio of biologic therapies and scientific discoveries.

Lumen

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 5, 2024 9:06 AM	71ed439b
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 9:06 AM	c98bb2f2
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	807480a6
crunchbase profile	general
li profile	general	Mar 5, 2024 9:06 AM	00b442c7
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 9:06 AM	f4c3c101
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

BIO:LUMEN

Lumen